Mosaicism in sporadic neurofibromatosis 2 patients

被引:74
作者
Kluwe, L [1 ]
Mautner, VF
机构
[1] Univ Hosp Eppendorf, Dept Neurosurg, Lab Brain Tumor Biol, Hamburg, Germany
[2] Gen Hosp Ochsenzoll, Dept Neurol, Hamburg, Germany
关键词
D O I
10.1093/hmg/7.13.2051
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
More than half of neurofibromatosis 2 (NF2) patients represent de novo mutations which could have occurred at either pre-zygotic or post-zygotic stages. A post-zygotic mutation can result in mosaicism, In four sporadic NF2 patients, we found NF2 mutations in only a portion of corresponding leukocytes, In two other sporadic patients, no mutations were found in leukocytes but constitutional NF2 mutations were suggested by identical mutations in different tumors from each patient. We screened leukocyte DNA from a total of 16 inherited and 91 sporadic NF2 patients, and found NF2mutations in 13 (81%) of the former and in 46 (51%) of the latter cases, The 30% difference in the rate of detection of mutations (P= 0.051) might be partially explained by mosaicism in a portion of sporadic NF2 patients who carry the mutations in such a fashion that their leukocytes are unaffected. Among sporadic cases, we found mutations more frequently in patients with severe phenotypes (59%) than in patients with mild phenotypes (23%) (difference of 36%, P = 0.007). Mosaicism might be more common in the latter patient group since small populations of mutation-bearing cells can in some cases result in mild phenotypes and can also lead to difficulties in identifying mutations. No mutations were found in eight patients suspected of having NF2, Mosaicism with an extremely small population of affected cells may explain the incomplete phenotypes in some of these patients and the lack of mutations in their leukocytes. These findings suggest that mosaicism is relatively common in NF2 and may have important implications for diagnosis, prognosis and genetic counseling.
引用
收藏
页码:2051 / 2055
页数:5
相关论文
共 32 条
[1]  
Ainsworth PJ, 1997, HUM MUTAT, V9, P452, DOI 10.1002/(SICI)1098-1004(1997)9:5<452::AID-HUMU12>3.3.CO
[2]  
2-V
[3]   THE IMPORTANCE OF GENETIC MOSAICISM IN HUMAN-DISEASE [J].
BERNARDS, A ;
GUSELLA, JF .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (21) :1447-1449
[4]  
BIJSMA EK, 1997, J MED GENET, V34, P934
[5]  
BOURN D, 1994, AM J HUM GENET, V55, P69
[6]  
Colman SD, 1996, AM J HUM GENET, V58, P484
[7]   A GENETIC-STUDY OF TYPE-2 NEUROFIBROMATOSIS IN THE UNITED-KINGDOM .1. PREVALENCE, MUTATION-RATE, FITNESS, AND CONFIRMATION OF MATERNAL TRANSMISSION EFFECT ON SEVERITY [J].
EVANS, DGR ;
HUSON, SM ;
DONNAI, D ;
NEARY, W ;
BLAIR, V ;
TEARE, D ;
NEWTON, V ;
STRACHAN, T ;
RAMSDEN, R ;
HARRIS, R .
JOURNAL OF MEDICAL GENETICS, 1992, 29 (12) :841-846
[8]   Spinal and cutaneous schwannomatosis is a variant form of type 2 neurofibromatosis: A clinical and molecular study [J].
Evans, DGR ;
Mason, S ;
Huson, SM ;
Ponder, M ;
Harding, AE ;
Strachan, T .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1997, 62 (04) :361-366
[9]   Genotype/phenotype correlations in type 2 neurofibromatosis (NF2): evidence for more severe disease associated with truncating mutations [J].
Evans, DGR ;
Trueman, L ;
Wallace, A ;
Collins, S ;
Strachan, T .
JOURNAL OF MEDICAL GENETICS, 1998, 35 (06) :450-455
[10]  
EVANS DGR, 1992, Q J MED, V84, P603